ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Benign Prostate Hyperplasia Drugs Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-39P2691
Home | Market Reports | Health| Men s Health
Global Benign Prostate Hyperplasia Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global Benign Prostate Hyperplasia Drugs Market Insights, Forecast to 2030

Code: QYRE-Auto-39P2691
Report
December 2024
Pages:110
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi
Coloplast
Pfizer Inc
Merck
GlaxoSmithKline PLC
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan plc
Boehringer Ingelheim

Benign Prostate Hyperplasia Drugs Market Size

The global Benign Prostate Hyperplasia Drugs market is projected to grow from US$ 3452.6 million in 2024 to US$ 4195.1 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.3% during the forecast period.

Benign Prostate Hyperplasia Drugs Market

Benign Prostate Hyperplasia Drugs Market

The goal of Benign prostate hyperplasia drugs is to reduce morbidity and prevent complications.Agents used include alpha-adrenergic blockers, 5-alpha-reductase inhibitors, phosphodiesterase -5 inhibitors and various combinations.
Market Analysis and Insights: Global Benign Prostate Hyperplasia Drugs Market
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Benign Prostate Hyperplasia Drugs market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Benign Prostate Hyperplasia Drugs, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Benign Prostate Hyperplasia Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Benign Prostate Hyperplasia Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Benign Prostate Hyperplasia Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Benign Prostate Hyperplasia Drugs revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Benign Prostate Hyperplasia Drugs Market Report

Report Metric Details
Report Name Benign Prostate Hyperplasia Drugs Market
Accounted market size in 2024 US$ 3452.6 million
Forecasted market size in 2030 US$ 4195.1 million
CAGR 3.3
Base Year 2024
Forecasted years 2025 - 2030
Segment by Type
  • Alpha Blocker
  • 5-Alpha Reductase Inhibitor
  • Phosphodiesterase-5 Inhibitor
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Sanofi, Coloplast, Pfizer, Merck, GlaxoSmithKline, Eli Lilly and Company, Abbott Laboratories, Teva Pharmaceuticals, Allergan, Boehringer Ingelheim
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Benign Prostate Hyperplasia Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Benign Prostate Hyperplasia Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 8: China by Type, and by Application, revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Benign Prostate Hyperplasia Drugs revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

How fast is Benign Prostate Hyperplasia Drugs Market growing?

Ans: The Benign Prostate Hyperplasia Drugs Market witnessing a CAGR of 3.3 during the forecast period 2025-2030.

What is the Benign Prostate Hyperplasia Drugs Market size in 2030?

Ans: The Benign Prostate Hyperplasia Drugs Market size in 2030 will be US$ 4195.1 million.

Who are the main players in the Benign Prostate Hyperplasia Drugs Market report?

Ans: The main players in the Benign Prostate Hyperplasia Drugs Market are Sanofi, Coloplast, Pfizer, Merck, GlaxoSmithKline, Eli Lilly and Company, Abbott Laboratories, Teva Pharmaceuticals, Allergan, Boehringer Ingelheim

What are the Application segmentation covered in the Benign Prostate Hyperplasia Drugs Market report?

Ans: The Applications covered in the Benign Prostate Hyperplasia Drugs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Benign Prostate Hyperplasia Drugs Market report?

Ans: The Types covered in the Benign Prostate Hyperplasia Drugs Market report are Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Others

Recommended Reports

Urology & Prostate Drugs

Male Health & Oncology

Cardiovascular & Hypertension

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Alpha Blocker
1.2.3 5-Alpha Reductase Inhibitor
1.2.4 Phosphodiesterase-5 Inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Benign Prostate Hyperplasia Drugs Market Perspective (2019-2030)
2.2 Global Benign Prostate Hyperplasia Drugs Growth Trends by Region
2.2.1 Benign Prostate Hyperplasia Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Benign Prostate Hyperplasia Drugs Historic Market Size by Region (2019-2024)
2.2.3 Benign Prostate Hyperplasia Drugs Forecasted Market Size by Region (2025-2030)
2.3 Benign Prostate Hyperplasia Drugs Market Dynamics
2.3.1 Benign Prostate Hyperplasia Drugs Industry Trends
2.3.2 Benign Prostate Hyperplasia Drugs Market Drivers
2.3.3 Benign Prostate Hyperplasia Drugs Market Challenges
2.3.4 Benign Prostate Hyperplasia Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Benign Prostate Hyperplasia Drugs by Players
3.1.1 Global Benign Prostate Hyperplasia Drugs Revenue by Players (2019-2024)
3.1.2 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Benign Prostate Hyperplasia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Benign Prostate Hyperplasia Drugs, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio
3.4.1 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostate Hyperplasia Drugs Revenue in 2023
3.5 Global Key Players of Benign Prostate Hyperplasia Drugs Head office and Area Served
3.6 Global Key Players of Benign Prostate Hyperplasia Drugs, Product and Application
3.7 Global Key Players of Benign Prostate Hyperplasia Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Benign Prostate Hyperplasia Drugs Breakdown Data by Type
4.1 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Type (2019-2024)
4.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2025-2030)
5 Benign Prostate Hyperplasia Drugs Breakdown Data by Application
5.1 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Application (2019-2024)
5.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
6.2 North America Benign Prostate Hyperplasia Drugs Market Size by Type
6.2.1 North America Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
6.2.2 North America Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
6.2.3 North America Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
6.3 North America Benign Prostate Hyperplasia Drugs Market Size by Application
6.3.1 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
6.3.2 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
6.3.3 North America Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
6.4 North America Benign Prostate Hyperplasia Drugs Market Size by Country
6.4.1 North America Benign Prostate Hyperplasia Drugs Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024)
6.4.3 North America Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
7.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Type
7.2.1 Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
7.2.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
7.2.3 Europe Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
7.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Application
7.3.1 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
7.3.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
7.3.3 Europe Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
7.4 Europe Benign Prostate Hyperplasia Drugs Market Size by Country
7.4.1 Europe Benign Prostate Hyperplasia Drugs Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024)
7.4.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
8.2 China Benign Prostate Hyperplasia Drugs Market Size by Type
8.2.1 China Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
8.2.2 China Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
8.2.3 China Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
8.3 China Benign Prostate Hyperplasia Drugs Market Size by Application
8.3.1 China Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
8.3.2 China Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
8.3.3 China Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
9.2 Asia Benign Prostate Hyperplasia Drugs Market Size by Type
9.2.1 Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
9.2.2 Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
9.2.3 Asia Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
9.3 Asia Benign Prostate Hyperplasia Drugs Market Size by Application
9.3.1 Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
9.3.2 Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
9.3.3 Asia Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
9.4 Asia Benign Prostate Hyperplasia Drugs Market Size by Region
9.4.1 Asia Benign Prostate Hyperplasia Drugs Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Benign Prostate Hyperplasia Drugs Market Size by Region (2019-2024)
9.4.3 Asia Benign Prostate Hyperplasia Drugs Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Benign Prostate Hyperplasia Drugs Introduction
11.1.4 Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.1.5 Sanofi Recent Developments
11.2 Coloplast
11.2.1 Coloplast Company Details
11.2.2 Coloplast Business Overview
11.2.3 Coloplast Benign Prostate Hyperplasia Drugs Introduction
11.2.4 Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.2.5 Coloplast Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Benign Prostate Hyperplasia Drugs Introduction
11.3.4 Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.3.5 Pfizer Recent Developments
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Benign Prostate Hyperplasia Drugs Introduction
11.4.4 Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.4.5 Merck Recent Developments
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Details
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Introduction
11.6.4 Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.6.5 Eli Lilly and Company Recent Developments
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Company Details
11.7.2 Abbott Laboratories Business Overview
11.7.3 Abbott Laboratories Benign Prostate Hyperplasia Drugs Introduction
11.7.4 Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.7.5 Abbott Laboratories Recent Developments
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Details
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Introduction
11.8.4 Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.8.5 Teva Pharmaceuticals Recent Developments
11.9 Allergan
11.9.1 Allergan Company Details
11.9.2 Allergan Business Overview
11.9.3 Allergan Benign Prostate Hyperplasia Drugs Introduction
11.9.4 Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.9.5 Allergan Recent Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Details
11.10.2 Boehringer Ingelheim Business Overview
11.10.3 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Introduction
11.10.4 Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024)
11.10.5 Boehringer Ingelheim Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Sanofi
Coloplast
Pfizer Inc
Merck
GlaxoSmithKline PLC
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan plc
Boehringer Ingelheim
List of Tables
    Table 1. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Alpha Blocker
    Table 3. Key Players of 5-Alpha Reductase Inhibitor
    Table 4. Key Players of Phosphodiesterase-5 Inhibitor
    Table 5. Key Players of Others
    Table 6. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 7. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Benign Prostate Hyperplasia Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 9. Global Benign Prostate Hyperplasia Drugs Market Share by Region (2019-2024)
    Table 10. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 11. Global Benign Prostate Hyperplasia Drugs Market Share by Region (2025-2030)
    Table 12. Benign Prostate Hyperplasia Drugs Market Trends
    Table 13. Benign Prostate Hyperplasia Drugs Market Drivers
    Table 14. Benign Prostate Hyperplasia Drugs Market Challenges
    Table 15. Benign Prostate Hyperplasia Drugs Market Restraints
    Table 16. Global Benign Prostate Hyperplasia Drugs Revenue by Players (2019-2024) & (US$ Million)
    Table 17. Global Benign Prostate Hyperplasia Drugs Revenue Share by Players (2019-2024)
    Table 18. Global Top Benign Prostate Hyperplasia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2023)
    Table 19. Global Benign Prostate Hyperplasia Drugs Industry Ranking 2022 VS 2023 VS 2024
    Table 20. Global 5 Largest Players Market Share by Benign Prostate Hyperplasia Drugs Revenue (CR5 and HHI) & (2019-2024)
    Table 21. Global Key Players of Benign Prostate Hyperplasia Drugs, Headquarters and Area Served
    Table 22. Global Key Players of Benign Prostate Hyperplasia Drugs, Product and Application
    Table 23. Global Key Players of Benign Prostate Hyperplasia Drugs, Product and Application
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 26. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type (2019-2024)
    Table 27. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 28. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type (2025-2030)
    Table 29. Global Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 30. Global Benign Prostate Hyperplasia Drugs Revenue Share by Application (2019-2024)
    Table 31. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 32. Global Benign Prostate Hyperplasia Drugs Revenue Share by Application (2025-2030)
    Table 33. North America Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 34. North America Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 35. North America Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 36. North America Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 37. North America Benign Prostate Hyperplasia Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. North America Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 39. North America Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 41. Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 42. Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 43. Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 44. Europe Benign Prostate Hyperplasia Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 45. Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 46. Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 47. China Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 48. China Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 49. China Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 50. China Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 51. Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 52. Asia Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 53. Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 54. Asia Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 55. Asia Benign Prostate Hyperplasia Drugs Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 56. Asia Benign Prostate Hyperplasia Drugs Market Size by Region (2019-2024) & (US$ Million)
    Table 57. Asia Benign Prostate Hyperplasia Drugs Market Size by Region (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2019-2024) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2025-2030) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 63. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2019-2024) & (US$ Million)
    Table 64. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2025-2030) & (US$ Million)
    Table 65. Sanofi Company Details
    Table 66. Sanofi Business Overview
    Table 67. Sanofi Benign Prostate Hyperplasia Drugs Product
    Table 68. Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 69. Sanofi Recent Developments
    Table 70. Coloplast Company Details
    Table 71. Coloplast Business Overview
    Table 72. Coloplast Benign Prostate Hyperplasia Drugs Product
    Table 73. Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 74. Coloplast Recent Developments
    Table 75. Pfizer Company Details
    Table 76. Pfizer Business Overview
    Table 77. Pfizer Benign Prostate Hyperplasia Drugs Product
    Table 78. Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 79. Pfizer Recent Developments
    Table 80. Merck Company Details
    Table 81. Merck Business Overview
    Table 82. Merck Benign Prostate Hyperplasia Drugs Product
    Table 83. Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 84. Merck Recent Developments
    Table 85. GlaxoSmithKline Company Details
    Table 86. GlaxoSmithKline Business Overview
    Table 87. GlaxoSmithKline Benign Prostate Hyperplasia Drugs Product
    Table 88. GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 89. GlaxoSmithKline Recent Developments
    Table 90. Eli Lilly and Company Company Details
    Table 91. Eli Lilly and Company Business Overview
    Table 92. Eli Lilly and Company Benign Prostate Hyperplasia Drugs Product
    Table 93. Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 94. Eli Lilly and Company Recent Developments
    Table 95. Abbott Laboratories Company Details
    Table 96. Abbott Laboratories Business Overview
    Table 97. Abbott Laboratories Benign Prostate Hyperplasia Drugs Product
    Table 98. Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 99. Abbott Laboratories Recent Developments
    Table 100. Teva Pharmaceuticals Company Details
    Table 101. Teva Pharmaceuticals Business Overview
    Table 102. Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Product
    Table 103. Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 104. Teva Pharmaceuticals Recent Developments
    Table 105. Allergan Company Details
    Table 106. Allergan Business Overview
    Table 107. Allergan Benign Prostate Hyperplasia Drugs Product
    Table 108. Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 109. Allergan Recent Developments
    Table 110. Boehringer Ingelheim Company Details
    Table 111. Boehringer Ingelheim Business Overview
    Table 112. Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Product
    Table 113. Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2019-2024) & (US$ Million)
    Table 114. Boehringer Ingelheim Recent Developments
    Table 115. Research Programs/Design for This Report
    Table 116. Key Data Information from Secondary Sources
    Table 117. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Benign Prostate Hyperplasia Drugs Market Share by Type: 2023 VS 2030
    Figure 3. Alpha Blocker Features
    Figure 4. 5-Alpha Reductase Inhibitor Features
    Figure 5. Phosphodiesterase-5 Inhibitor Features
    Figure 6. Others Features
    Figure 7. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 8. Global Benign Prostate Hyperplasia Drugs Market Share by Application: 2023 VS 2030
    Figure 9. Hospital Case Studies
    Figure 10. Clinic Case Studies
    Figure 11. Other Case Studies
    Figure 12. Benign Prostate Hyperplasia Drugs Report Years Considered
    Figure 13. Global Benign Prostate Hyperplasia Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 14. Global Benign Prostate Hyperplasia Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Benign Prostate Hyperplasia Drugs Market Share by Region: 2023 VS 2030
    Figure 16. Global Benign Prostate Hyperplasia Drugs Market Share by Players in 2023
    Figure 17. Global Top Benign Prostate Hyperplasia Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2023)
    Figure 18. The Top 10 and 5 Players Market Share by Benign Prostate Hyperplasia Drugs Revenue in 2023
    Figure 19. North America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. North America Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
    Figure 21. North America Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
    Figure 22. North America Benign Prostate Hyperplasia Drugs Market Share by Country (2019-2030)
    Figure 23. United States Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Canada Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Europe Benign Prostate Hyperplasia Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 26. Europe Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
    Figure 27. Europe Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
    Figure 28. Europe Benign Prostate Hyperplasia Drugs Market Share by Country (2019-2030)
    Figure 29. Germany Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. France Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. U.K. Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Italy Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Russia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Nordic Countries Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. China Benign Prostate Hyperplasia Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 36. China Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
    Figure 37. China Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
    Figure 38. Asia Benign Prostate Hyperplasia Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 39. Asia Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
    Figure 40. Asia Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
    Figure 41. Asia Benign Prostate Hyperplasia Drugs Market Share by Region (2019-2030)
    Figure 42. Japan Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. South Korea Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. China Taiwan Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Southeast Asia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. India Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Australia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Size YoY (2019-2030) & (US$ Million)
    Figure 49. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Type (2019-2030)
    Figure 50. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Application (2019-2030)
    Figure 51. Middle East, Africa, and Latin America Benign Prostate Hyperplasia Drugs Market Share by Country (2019-2030)
    Figure 52. Brazil Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Mexico Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Turkey Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. Saudi Arabia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Israel Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 57. GCC Countries Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 58. Sanofi Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 59. Coloplast Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 60. Pfizer Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 61. Merck Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 62. GlaxoSmithKline Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 63. Eli Lilly and Company Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 64. Abbott Laboratories Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 65. Teva Pharmaceuticals Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 66. Allergan Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 67. Boehringer Ingelheim Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2019-2024)
    Figure 68. Bottom-up and Top-down Approaches for This Report
    Figure 69. Data Triangulation
    Figure 70. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Benign Prostatic Hyperplasia Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Benign Prostatic Hyperplasia Equipment Market Research Report 2025
Benign Prostatic Hyperplasia BPH Treatment Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Benign Prostatic Hypertrophy Medication Market Research Report 2024
Benign Prostatic Hyperplasia Treatment Equipments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Benign Prostatic Hyperplasia Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Benign Prostatic Hyperplasia Treatment Market Insights Forecast to 2030
BPH Treatment Equipment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Urology Drugs Market Insights Forecast to 2030
Global Hypertension and Heart Failure Drugs Market Insights Forecast to 2030
Global Alfuzosin Market Insights Forecast to 2030
Global Benign Prostatic Hyperplasia BPH Drugs Market Insights Forecast to 2030
Global Lipid regulating Drugs Market Insights Forecast to 2030
Medicine Treat BPH Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Prostate Cancer Medicine Market Insights Forecast to 2030
Urological Medications Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Benign Prostatic Hyperplasia BPH Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Intraocular Antihypertensive Market Research Report 2025
Global Dutasteride API Market Research Report 2024
Global Tamsulosin Market Insights Forecast to 2030

RELATED REPORTS

Global Testicular Cancer Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26B6701
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Prostate Cancer Biomarker Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12M6232
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Benign Prostatic Hyperplasia Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-39G5907
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Prostate Cancer Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-7B2445
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions